DRGV yields 1000000.00% · ABBV yields 3.06%● Live data
📍 DRGV pulled ahead of the other in Year 1
Combined, DRGV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRGV + ABBV for your $10,000?
Dragon Capital Group, Corp., through its subsidiaries, provides software solutions for businesses primarily in the People's Republic of China and the United States. It offers various software applications, including network software, gas pipeline risk assessment system, e-business software development, financial and enterprise information management systems, and computerized automation control applications for commercial and residential buildings, commercial third-generation wireless applications, and mobile business solutions, and multi imaging applications. The company develops commercial 3G wireless applications and mobile business solutions for the human resources, mobile banking, food, beverage, and entertainment industries. In addition, it provides an ERS software system for enterprises to manage accounting, distribution, inventory, and sales; and sells and distributes electronic equipments and devices, and technology solutions to financial institutions, telecommunication companies, hospitals, supermarkets, airports, railway stations, and various government agencies. Additionally, it provides support services in general business consulting, formation of joint ventures, access to capital markets, merger and acquisition transactions consulting, business valuation, and revenue growth strategies. The company was formerly known as Dragon Venture and changed its name to Dragon Capital Group, Corp. in March 2005. Dragon Capital Group, Corp. was incorporated in 1977 and is headquartered in Shanghai, China.
Full DRGV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.